The Art of the Crackdown: Trump's Hardline Drug Strategy

In a popular CNN video from 2010, we see him talking to his then 4-year-old son Barron in his office. When discussing Barron’s future, the message is clear : “No drugs, no alcohol, no cigarettes!”. In 2018, Trump left no room for doubt when he stated: “If we don't get tough on drug dealers, we're wasting our time [...] That toughness includes the death penalty”.

As he begins his second term as President of the United States, his commitment to a hardline approach against drug trafficking remains central to his agenda. Trump has promised to intensify the policies he implemented during his first term. His appointments and an updated strategy suggest a doubling-down of his War on Drugs, launched back in 2017. Shortly after his second inauguration, he appointed Derek Maltz, a former counternarcotics agent with decades of experience as acting Drug Enforcement Administration (DEA) administrator.

The DEA has long been at the forefront of Washington’s efforts to disrupt transnational drug trafficking networks. Over the past decade, drug smuggling into the U.S. has surged dramatically, with Mexican cartels playing a central role in trafficking fentanyl, heroin, and other opioids, contributing to a devastating rise in overdose deaths. The U.S. records about 100,000 overdose deaths per year, largely driven by synthetic opioids such as fentanyl. Opioids account for nearly 75% of these fatalities, while methamphetamine and cocaine remain widespread. The smuggling networks have become increasingly sophisticated, using a mix of traditional methods and modern technology to bypass U.S. law enforcement.

During his first term in office, Trump particularly targeted these Mexican cartels, which supply much of the fentanyl that floods U.S. communities. With Maltz at the helm, the DEA is expected to intensify operations along the U.S.-Mexico border and focus on dismantling the cartels’ supply chains —in a muscular fashion should  the situation demand it. 

In his second term, Trump will continue to focus on Latin American drug cartels and the opioid crisis wreaking havoc on his country’s population. His previous administration used a mix of diplomatic pressure and incentives to push Latin American countries to take stronger action against the drug trade. The United States-Mexico-Canada Agreement (USMCA), which replaced the North American Free Trade Agreement (NAFTA), included provisions to encourage Mexico to curb drug production and trafficking. Trump also signed the SUPPORT Act of 2018, which expanded access to treatment, prevention programs, and efforts to curb illegal drug trafficking.

Central to Trump’s renewed War on Drugs is a more assertive interpretation of the Monroe Doctrine. Originally aimed at preventing European interference in the Western Hemisphere, Trump’s version seeks to block external influence from countries like China and Russia, particularly in the context of drug trafficking and regional politics. 

Trump has repeatedly expressed concerns about China’s growing presence in Latin America, especially in infrastructure and trade. Beijing plays a pivotal role in the global drug trade as a primary exporter of precursor chemicals used in the production of synthetic drugs, including methamphetamine and fentanyl. Many of these chemicals are legally manufactured and exported to Latin America, where they are diverted into illicit drug manufacturing by cartels. This supply chain has fueled the growth of drug production in the region, exacerbating the narcotics crisis in the Americas and contributing to surging overdose rates in the U.S. The first Trump administration has sought to ensure that countries like Venezuela, where Chinese and Russian influence is growing, do not hinder U.S. efforts to combat drug cartels and authoritarian regimes in the region.

This somewhat revised version of the Monroe Doctrine signals Trump’s determination to maintain U.S. dominance in the hemisphere, limiting foreign interference that complicates his policies, especially in the fight against the drug trade. In doing so, the U.S. demonstrates its willingness to pressure regional governments to align with its priorities regarding the control of narcotics.

Another key element of Trump’s second-term strategy is his decision to withdraw from the WHO, signaling a strategic shift toward more unilateral action on drug policy. China’s population being at least four times larger than that of the U.S., Trump argued that the scale of Washington’s contribution to the yearly WHO budget was unfair: “China pays $39 million [per year], and we pay $500 million, [although] China's a bigger country.” 

Withdrawal from the WHO will give the U.S. greater freedom to make independent decisions about its public health policies without being bound by international agreements or the WHO’s guidelines. It will also allow the U.S. to redirect significant funding toward domestic health programs or other international initiatives that align more closely with U.S. interests. The consequences of this bold move will be far-reaching, especially in terms of international collaboration on health emergencies like pandemics.
In 2023, Trump proclaimed: “We're going to be asking everyone who [...] gets caught selling drugs to receive the death penalty for their heinous acts”. Drug lords across the American continent still have nightmares about Trump’s first term in office. One thing is sure, he is determined to go after them.